The Food and Drug Administration (FDA) has approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn; Regeneron Pharmaceuticals), a mixture of three monoclonal antibodies, for treatment of Zaire ebolavirus (Ebola virus) inflection in adult and pediatric patients.

Zaire ebolavirus is one of four Ebolavirus species that can cause a potentially fatal human disease. Ebola virus is transmitted through direct contact with blood, body fluids and tissues of infected people or wild animals, as well as with surfaces and materials contaminated with these fluids. Individuals who provide care for people with Ebola virus are at the highest risk for infection.

Inmazeb targets the glycoprotein that is on the surface of Ebola virus. Glycoprotein attaches to the cell receptor and fuses the viral and host cell membranes allowing the virus to enter the cell. The three antibodies that make up Inmazeb can bind to this glycoprotein simultaneously and block attachment and entry of the virus. Inmazeb has been granted Orphan Drug designation and Breakthrough Therapy designation.

Food and Drug Administration (FDA). FDA Approves First Treatment for Ebola Virus [news release]. October 14, 2020. Available at: click here. Accessed October 15, 2020.